■ MATERIAL WEAKNESS WATCH
Nasdaq · CIK 0001759425

MIRM Mirum Pharmaceuticals, Inc.

B
75 / 100
Material weaknesses
2
Restatements
0
Auditor changes
0
Late filings
0
Quarters with open weakness
1
Remediations
1
Deductions
40
Remediation credit
15

Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.

Disclosures, in the company's words

  • Material weakness10-Q · filed 2026-11-03source filing ↗
    “and over the precision of management review controls and the sufficiency of control evidence related to prospective financial information used to determine the fair value of acquired developed technology”
  • Material weakness10-Q · filed 2026-11-03source filing ↗
    “management identified material weaknesses in the design of controls and level of evidence retained over the existence and valuation of inventory, including the controls over existence of inventory located at third parties and the net realizable value assessment of on-hand inventory and future purchases under firm commitments”

Remediation disclosed

  • 10-Q · filed 2026-11-03 · source filing ↗
    “Although we have been and are taking steps to improve our internal control over financial reporting and remediated these material weaknesses, the measures we have taken to date may not be sufficient to avoid potential future material weaknesses.”

Filings read

Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.